- NO PUBLIC OFFERING - NO INVITATION to subscribe for or purchase securities - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN. -

SHOP APOTHEKE EUROPE announces price range for IPO

- Price range set at EUR 28.00 to EUR 35.00 per share

- Targeted gross primary proceeds of c. EUR 100 million

- Proceeds are mainly designated to finance growth and market penetration in Continental Europe

- Start of offer period after approval and publication of prospectus

Venlo/Cologne, 28 September 2016 - SHOP APOTHEKE EUROPE NV ('SHOP APOTHEKE EUROPE' or the 'Company'), one of the leading online pharmacies in Continental Europe, in coordination with Berenberg and Citigroup as Joint Global Coordinators, has set the price range for its initial public offering ('IPO') at EUR 28.00 to EUR 35.00 per share.

SHOP APOTHEKE EUROPE intends to raise c. EUR 100 million gross primary proceeds through an offering of up to 3,571,428 newly issued shares (number of shares to be issued dependent on price determined in bookbuilding process in order to achieve envisaged gross proceeds) increasing the Company's current number of shares of 5,498,450. Proceeds from the primary offering are mainly designated to finance SHOP APOTHEKE EUROPE's growth, supporting further growth and market penetration in Continental Europe and to invest in further expansion and automation of its logistics and infrastructure as well as to repay shareholder loans.

The final offer price will be determined on the basis of a bookbuilding process still to be undertaken. This announcement does not, and shall not, in any circumstances constitute a public offering, nor an offer to subscribe any securities in any jurisdiction. Purchase orders for shares in the Company can only be submitted and will be only accepted during the offer period The offer period will begin one day after the securities prospectus has been approved by the Dutch Authority for the Financial Markets (AFM), notified to the German Federal Financial Supervisory Authority (BaFin) and published. The approval of such prospectus by the AFM is expected in due course.

Detailed information about the IPO will be contained in the SHOP APOTHEKE EUROPE prospectus, which will be published once it has been approved by the AFM and been notified to the German Federal Financial Supervisory Authority (BaFin).

Berenberg and Citigroup have been appointed Joint Global Coordinators, and, together with Commerzbank as Joint Bookrunners in connection with the IPO. Lilja & Co. serves as independent advisor to the management and the owners of SHOP APOTHEKE EUROPE.

ABOUT SHOP APOTHEKE EUROPE

SHOP APOTHEKE EUROPE is one of Continental Europe's leading online pharmacies with a portfolio that focuses on OTC medication and pharmacy-related BPC products. The company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, TÜV-certified shop-apotheke.com is the market leader in terms of traffic, delivering a broad range of approximately 100,000 original products to about 1.5 million active customers quickly and at a good price. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated over EUR 125 million in revenues in the financial year 2015. Headquartered in Venlo (Netherlands), SHOP APOTHEKE EUROPE also has an administration site for its sales and marketing units in Cologne (Germany).

MEDIA CONTACTS

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Mobile: +49 172 297 62 43
Email: presse@shop-apotheke.com

DISCLAIMER.
This announcement does not, and shall not, in any circumstances constitute a public offering, nor an offer to subscribe any securities in any jurisdiction. In particular, this communication is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This communication does not constitute or form part of an offer of securities for sale or solicitation of an offer to purchase securities in the United States, Canada, Australia, Japan or in any other jurisdiction in which such offer may be restricted. The securities referred to in this communication have not been, and will not be, registered under the US Securities Act of 1933, as amended (the 'Securities Act'), and may not be offered or sold in the United States, except on the basis of an applicable exemption from the registration requirements or in a transaction not subject to the registration requirements of the Securities Act. There will be no public offering of securities in the United States.
In the United Kingdom, this communication is directed only at persons who: (i) are qualified investors within the meaning of the Financial Services and Markets Act 2000 (as amended) and any relevant implementing measures and/or (ii) are outside the United Kingdom or (iii) have professional experience in matters relating to investments and fall within the definition of 'investment professionals' contained in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the 'Order') or are persons falling within article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as 'Relevant Persons'). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
This communication contains statements related to future business and financial performance and future events or developments involving SHOP APOTHEKE EUROPE that may constitute forward-looking statements. These statements may be identified by words such as 'expect', 'intend', 'look forward to', 'believe', 'will' or other words of similar meaning. Such statements are based on current expectations and certain assumptions of SHOP APOTHEKE EUROPE's management, of which many are out of our control. These are subjects to a number of risks and uncertainties. Should one or more of this risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of SHOP APOTHEKE EUROPE may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. SHOP APOTHEKE EUROPE does not intend or assume any obligation to update or revise these forward-looking statements in light of developments which differ from those anticipated.
This communication is not a prospectus. Investors should not purchase or subscribe for any securities
referred to in this communication except on the basis of information in the prospectus to be issued by
SHOP APOTHEKE EUROPE in connection with the offering of such securities.